Mouse Survival Motor Neuron Alleles That Mimic SMN2 Splicing and Are Inducible Rescue Embryonic Lethality Early in Development but Not Late

Spinal muscular atrophy (SMA) is caused by low survival motor neuron (SMN) levels and patients represent a clinical spectrum due primarily to varying copies of the survival motor neuron-2 (SMN2) gene. Patient and animals studies show that disease severity is abrogated as SMN levels increase. Since therapies currently being pursued target the induction of SMN, it will be important to understand the dosage, timing and cellular requirements of SMN for disease etiology and potential therapeutic intervention. This requires new mouse models that can induce SMN temporally and/or spatially. Here we describe the generation of two hypomorphic Smn alleles, SmnC-T-Neo and Smn2B-Neo. These alleles mimic SMN2 exon 7 splicing, titre Smn levels and are inducible. They were specifically designed so that up to three independent lines of mice could be generated, herein we describe two. In a homozygous state each allele results in embryonic lethality. Analysis of these mutants indicates that greater than 5% of Smn protein is required for normal development. The severe hypomorphic nature of these alleles is caused by inclusion of a loxP-flanked neomycin gene selection cassette in Smn intron 7, which can be removed with Cre recombinase. In vitro and in vivo experiments demonstrate these as inducible Smn alleles. When combined with an inducible Cre mouse, embryonic lethality caused by low Smn levels can be rescued early in gestation but not late. This provides direct genetic evidence that a therapeutic window for SMN inductive therapies may exist. Importantly, these lines fill a void for inducible Smn alleles. They also provide a base from which to generate a large repertoire of SMA models of varying disease severities when combined with other Smn alleles or SMN2-containing mice.


Introduction
The survival motor neuron (SMN) gene is ubiquitously expressed and encodes an essential protein that is required by all cells [1]. Low levels of SMN cause proximal spinal muscular atrophy (SMA), an autosomal recessive disease, and a common genetic cause of infant mortality [2,3]. It is pathologically characterized by selective loss of lower motor neurons within the spinal cord, causing progressive muscle atrophy due to denervation. Proximal muscles within the limbs and trunk are more affected than distal muscle groups, but ultimately all muscles succumb to denervation causing paralysis, respiratory deficiency and ultimately death.
Clinically, SMA is heterogeneous and has been divided into three major groups based upon age at onset and achieved motor milestones [4,5]. Genetically SMA is homogenous in that all forms of the disease are caused by homozygous deletion, rare subtle mutations, or gene conversion of the survival motor neuron-1 (SMN1) gene with concurrent retention of a linked paralog, survival motor neuron-2 (SMN2) [2,6,7]. Both SMN genes reside in a duplicated genomic region at 5q13, are transcribed, translated and 99.9% identical [2,8,9]. The key difference is a single, translationally silent nucleotide transition (C to T) at the +6 position within exon 7 that functionally distinguishes SMN1 from SMN2 and prevents SMN2 from fully compensating for SMN1 loss [2,9,10]. SMN1 contains a ''C'' nucleotide and produces full-length SMN transcripts (FL-SMN). In contrast, SMN2 contains a ''T'' nucleotide and primarily produces transcripts that lack exon 7 (SMND7) and a small amount of FL-Smn. This is due to the simultaneous disruption of an ASF/SF2 exon splice enhancer (ESE) and creation of an exon splice silencer (ESS) in SMN2 [11,12].
The SMN2 copy number in an individual can vary from one to six and it is this variability that is mainly responsible for the clinical spectrum seen in SMA patients [13]. Since every SMA patient has at least one functioning SMN2 gene, it has become a target for therapeutic interventions, and most pre-clinical studies have focused on up-regulating SMN levels by some means [14,15,16,17,18,19,20,21,22,23,24]. An important point of all SMN-dependent therapies is an understanding of when, where and how much SMN induction is required, and how this might change for the various clinical forms of SMA. The dosage, timing and cellular requirements of SMN in different tissues should not be overlooked as there is mounting evidence in humans and mice that suggest non-motor neuron targets such as heart, autonomic and vascular systems may require consideration [25,26,27,28]. Although some data is already available and demonstrates a therapeutic window of opportunity to affect a benefit for severe SMA mice [15,17,29], a new panel of mice is required in which SMN can be induced temporally and/or spatially to refine and extend current results.
In this study, we report the generation and characterization of two Smn progenitor alleles, Smn C-T-Neo and Smn 2B-Neo . They were designed to stimulate Smn exon 7 alternative splicing, which normally does not occur in the mouse [30,31]. Smn C-T-Neo and Smn 2B-Neo are severe hypomorphs that cause embryonic lethality when in a homozygous state due to the presence of a loxPflanked neomycin (neo) gene resistance cassette that hinders Smn expression. However, in the presence of Cre recombinase, the embryonic lethality can be rescued by neo excision, while still maintaining Smn exon 7 alternative splicing via our introduced mutations. In vitro and in vivo experiments demonstrate the utility of these mice to be used as inducible Smn alleles when combined with Cre transgenic lines. Using a tamoxifen-inducible Cre line we show that embryonic lethality can be rescued early in gestation but not late. As a final point, the Smn C-T-Neo and Smn 2B-Neo lines were specifically designed to be progenitor alleles, so that potentially three useful lines of mice could be generated from each targeting event. Importantly, these lines alter the endogenous Smn locus so they mimic SMN2 exon 7 alternative splicing and the situation of SMA patients, which is reduction of Smn protein levels, not absence of protein. When used as inducible Smn alleles, they increase Smn levels under the normal regulation of the endogenous locus, while still mimicking SMN2 splicing.

Results
Generation and germline transmission of Smn C-T-Neo and Smn 2B-Neo alleles Based on our previous studies we designed two replacement vectors, p(Smn C-T-Neo ) and p(Smn 2B-Neo ) and introduced two different mutations into the endogenous Smn locus by homologous recombination. The first mimics human SMN2 and is a C-T transition at position 6 of exon 7, referred to hereafter as the C-T mutation. The second mutation alters the central portion of the ESE where hTra2-Beta1 binds Smn exon 7 (GGA to TTT), and we refer to this mutation as the 2B mutation [32] ( Figure 1A). It is known that this binding site is important for SMN exon 7 processing [33]. For both replacement vectors the positive selection cassette, pgk-neo, was inserted into the unique BamHI site ,180 bp distal to exon 7 in the antisense orientation to Smn transcription. This was specifically done as an additional way to potentially hinder Smn processing. We also flanked (''floxed'') the pgk-neo cassette with loxP sites so that it could be excised with Cre recombinase in future experiments to leave the endogenous locus with a minimal amount of alteration.
Homologous recombinant embryonic stem cell clones were identified by Southern blot hybridization ( Figure 1B) and two independent clones for each construct used to generate chimeras. Germline transmission was confirmed through direct sequencing of Smn exon 7 PCR products ( Figure 1C). We refer to these progenitor lines as Smn C-T-Neo (official name Smn1 tm2Cdid ) and Smn 2B-Neo (official name Smn1 tm1Cdid ) as they retain the floxed pgk-neo selection cassette within Smn intron 7. All subsequent experiments Figure 1. Generation of mutant Smn alleles. (A) Gene targeting strategy to introduce the C-T and 2B mutation into Smn exon 7 using the gene targeting vectors pSmnC-T-Neo and pSmn2B-Neo. (B) Southern blot analysis of BamH I and Pst I digested DNA from neo resistant ES cell clones identified homologous recombinants. Two clones from each were used to perform blastocyst injections. (C) Germline transmission of Smn C-T-Neo and Smn 2B-Neo alleles were determined by direct sequencing of Smn exon 7 PCR products from heterozygous mice. The C-T mutation corresponds to the nucleotide transition within exon 7 of the SMN2 gene. The 2B mutation corresponds to a mutation within the splice enhancer region 2B, changing GGA to TTT [32]. doi:10.1371/journal.pone.0015887.g001 reported herein were performed after backcrossing to C57Bl/6 mice for at least three generations.

Smn C-T-Neo and Smn 2B-Neo alleles express very small amounts of Smn
To evaluate the effects of C-T-Neo and 2B-Neo mutations on Smn exon 7 processing, all major organs including spinal cord and skeletal muscle from postnatal tissues of heterozygous mice were analyzed by reverse transcription-polymerase chain reaction (RT-PCR). Smn C-T-Neo/WT mice produced both FL-Smn and D7Smn transcripts as did Smn 2B-Neo/WT mice (data not shown). We performed a series of intercrosses for each allele during the course of this study. Of 229 and 281 pups genotyped at weaning from Smn C-T-Neo/WT and Smn 2B-Neo/WT intercrosses, respectively, none were found to be homozygous (Table 1). To identify when during development Smn C-T-Neo/C-T-Neo and Smn 2B-Neo/2B-Neo embryos were dying, we performed a series of timed matings. For Smn C-T-Neo/WT intercrosses at 9.5 days post-coitum (E9.5), a total of 58 embryos were analyzed. While near mendelian ratios of wild type (Smn WT/WT ), heterozygous (Smn C-T-Neo/WT ) and homozygous mutants (Smn C-T-Neo/C-T-Neo ) were identified by genotyping, developmental delays of homozygous mutant Smn C-T-Neo/C-T-Neo embryos (11/58; 19%) were visible (Table 1 and Figure 2, panels a-h). Although at E12.5 we could still detect Smn C-T-Neo/C-T-Neo embryos (5/56; 9%), it was clear that all were developmentally delayed and some were undergoing resorption (Table 1 and Figure 2, panels i-p). By E15.5 only wild type and heterozygous Smn C-T-Neo/WT embryos were present (Table 1).
Our results for embryo analysis from Smn 2B-Neo/WT intercrosses were more dramatic. We analyzed 84 embryos at E9.5 and while we could detect Smn 2B-Neo/2B-Neo homozygotes (14/84; 17%), these embryos were more developmentally delayed than the Smn C-T-Neo/C-T-Neo embryos and were starting to be reabsorbed (Table 1 and Figure 2 panels a'-h'). At E12.5 all Smn 2B-Neo/2B-Neo homozygotes that we could detect were dead and at different levels of resorption (Table 1 and Figure 2, panels i'-p'). By E15.5 only wild type and heterozygous Smn 2B-Neo/WT embryos were present ( Table 1).
The embryonic lethality of Smn C-T-Neo/C-T-Neo and Smn 2B-Neo/2B-Neo embryos occurs later than Smn D7/D7 embryos, who die at E7.5 [34,35]. This suggested that a small amount of FL-Smn was being produced. To determine whether this was the case, we analyzed RNA from E9.5 wild type, heterozygous and homozygous Smn C-T-Neo and Smn 2B-Neo embryos by RT-PCR. Both FL-Smn and D7Smn were produced from heterozygous and homozygous Smn C-T-Neo and Smn 2B-Neo embryos in contrast to wild type Smn embryos (Smn WT ) ( Figure 3A). Furthermore, the Smn C-T-Neo allele consistently produced more transcripts that contained Smn exon 7 than the Smn 2B-Neo allele. Direct sequencing of the FL-Smn amplicon from Smn C-T-Neo/C-T-Neo embryos identified only the mutant ''T'' nucleotide at position +6 of Smn exon 7, as would be expected from homozygous mutant embryos ( Figure 3B). Likewise, FL-Smn amplicons from Smn 2B-Neo/2B-Neo embryos only expressed the 2B (TTT) mutation (data not shown).
To quantify the amount of FL-Smn and D7Smn transcripts that were produced in each of the genotypes from our intercross experiments, we designed two novel taqman assays for use in quantitative reverse transcription PCR (qRT-PCR). The first assay specifically detected Smn exon 7 in the presence of either the wild type, C-T or 2B mutation with similar efficiency. The second assay detected D7Smn transcripts. The values of FL-Smn from our Smn C-T-Neo and Smn 2B-Neo genotypes were compared to the expression of Smn WT E9.5 embryos derived from the same intercross to reduce variability. Overall, the amount of FL-Smn varied with our different genotypes ( Figure 3C and Table 2). Smn C-T-Neo/C-T-Neo embryos produced 2065% FL-Smn, whereas Smn 2B-Neo/2B-Neo embryos produced 1563% and these values were not statistically significant from each other (p = 0.43). This indicated that each Smn C-T-Neo and the Smn 2B-Neo allele produced ,10% and ,7.5% FL-Smn transcripts, respectively. These results are consistent with Smn C-T-Neo/WT (62612%) and Smn 2B-Neo/WT (5967%) embryos, if you consider that ,50% of FL-Smn transcripts are derived from the Smn WT allele ( Figure 3C and Table 2).
We also quantified the amount of D7Smn from our Smn C-T-Neo and Smn 2B-Neo genotypes by comparing them to D7Smn transcripts derived from spinal cord samples of Smn D7/WT mice [34]. Smn 2B-Neo/2B-Neo embryos expressed the greatest amount of D7Smn transcripts, whereas the Smn C-T-Neo/WT embryos expressed the least ( Figure 3A and 3C). Using this data in conjunction with our FL-Smn data we were able to generate a FL-Smn: D7Smn ratio for each genotype using the DDCt values. The ratio for Smn D7/WT mice was approximately equal to 1.0 (1.02260.018) and served as a control. The wild type allele (WT) only produces transcripts that contain Smn exon 7, whereas the Smn D7 allele only produces transcripts that lack exon 7 due to the absence of the exon in the genome of this allele [34]. In comparison, Smn C-T-Neo/WT mice produced about 12fold more (11.9860.929) FL-Smn than D7Smn transcripts. However, in homozygous embryos (Smn C-T-Neo/C-T-Neo ) the ratio was almost equal to 1.0 (0.98960.068) and this is consistent with the visual inspection of end-point RT-PCR ( Figure 3A). Interestingly, we found the FL-Smn: D7Smn ratio to be 10-fold less in Smn 2B-Neo/2B-Neo embryos (0.17860.022) as compared to Smn C-T-Neo/C-T-Neo embryos even though the amount of FL-Smn produced from either the Smn C-T-Neo or Smn 2B-Neo allele was not significantly different (p = 0.43). The change in ratio is due to the high levels of D7Smn transcripts that Smn 2B-Neo/2B-Neo embryos produced and is consistent with the splicing pattern and transcript ratios of SMN2 where the majority of SMN2 transcripts lack exon 7. To correlate FL-Smn transcripts to Smn protein we performed western blot analysis of single E9.5 embryos for each possible genotype. We had difficulty detecting Smn in homozygous mutant embryos, and the level varied between mutants of the same genotype ( Figure 3D). In general, the level of Smn correlated with the severity of the mutant embryo when we retrospectively compared Smn levels to our whole mount mutant embryo images ( Figure 3D and Figure 2). The level of Smn protein in Smn C-T-Neo/C-T-Neo embryos ranged from 2-5% and in Smn 2B-Neo/2B-Neo embryos it was about 1-3%. This was an unexpected finding based on our FL-Smn expression data from Smn C-T-Neo/C-T-Neo and Smn 2B-Neo/2B-Neo embryos and was most likely caused by the compromised physiological state of the SMA embryos, a lack of stability of higher order Smn complexes from low Smn levels and transcriptional and/or translational hindrance from the floxed pgk-neo cassette. Since the later was the only one that we could directly test, we removed the floxed pgk-neo cassette from the germline using homozygous EIIa-Cre transgenic mice that ubiquitously express Cre recombinase very early in embryogenesis [36]. This increased Smn protein levels from ,5% for homozygous Smn C-T-Neo and Smn 2B-Neo embryos to .30% for a single Smn C-T allele and ,16% for a single Smn 2B allele (data not shown and will be reported elsewhere). Collectively, these results confirm that our Smn C-T-Neo and Smn 2B-Neo alleles are severe hypomorphs. They express very low amounts of Smn due to the nature of our introduced mutations as well as the presence of a floxed pgk-neo selection cassette that hinders Smn expression. These alleles are ''repairable'' and have the potential to be used as inducible Smn alleles that mimic SMN2 splicing. To determine this directly, the following in vitro and in vivo experiments were designed to address the ability of Smn C-T-Neo and Smn 2B-Neo alleles to be utilized as inducible Smn alleles by excision of the floxed pgk-neo cassette.

Induction of Smn expression in vitro
We determined the ability of our progenitor alleles to induce Smn levels through excision of the floxed pgk-neo cassette in vitro using primary murine embryonic fibroblasts (MEFs). For these experiments, we used our Smn C-T-Neo allele in combination with a tamoxifen (TM) inducible Cre allele, Cre Esr1 [37]. We established and cultured MEF lines from two Smn C-T-Neo/WT ;Cre Esr1 embryos and compared untreated MEF cultures to those treated with TM. Excision of floxed pgk-neo by Cre Esr1 was monitored at the DNA level by three primer PCR analysis ( Figure 4A). The reaction amplified all three possible Smn alleles: WT (470 bp), C-T-Neo   Figure 4B, lanes 4 and 5). A low level of excision was also noted in cells without TM treatment; we attributed this to the previously reported ,0.1% spontaneous Cre activity that was reported for this line [37] ( Figure 4B, lanes 2 and 3). We then correlated pgk-neo excision with an increase in FL-Smn expression by directly sequencing RT-PCR products from treated and untreated MEFs. A clearly discernable ''T'' nucleotide was present in those cells treated with TM and absent in the untreated cultures indicating an increase of Smn expression specifically from our mutant allele ( Figure 4C). This was substantiated and quantified by qRT-PCR analysis which showed an 83% increase in FL-Smn transcripts and a 30% reduction in D7Smn transcripts between treated and untreated cultures ( Figure 4D). Therefore, addition of tamoxifen to cultures of Smn C-T-Neo/WT ;Cre Esr1 MEFs increased FL-Smn expression through excision of the floxed pgk-neo cassette in Smn intron 7 and demonstrates the inducible nature of these alleles in vitro.
The ability of our Smn alleles to be Cre responsive in post natal somatic tissues was determined by single intraperitoneal (i.p.) injections [9 mg/40 g body weight] of TM or vehicle (corn oil) to 2-4 month old Smn C-T-Neo/WT ;Cre Esr1 mice. They were euthanized five days postinjection and DNA from kidney, spinal cord, skeletal muscle, forebrain and cerebellum were used as template in PCR to determine floxed pgk-neo excision. Vehicle injected Smn C-T-Neo/WT ;Cre Esr1 mice had a low level of DNA excision consistent with background levels of Cre Esr1 ( Figure 5A Induction of Smn in Smn C-T-Neo/C-T-Neo ;Cre Esr1 embryos early, but not late, rescues embryonic lethality The early lethality of Smn C-T-Neo/C-T-Neo embryos was determined to be caused by low Smn levels, thus we next sought to determine when during development, if at all, we could increase Smn levels and rescue the embryonic lethality phenotype. To this end we crossed Smn C-T-Neo/WT females to Smn C-T-Neo/WT ;Cre Esr1 males in order to produce Smn C-T-Neo/C-T-Neo ;Cre Esr1 embryos. Without TM  treatment these embryos should undergo complete resorption between E12.5 and E15.5 ( Figure 2 and Table 1). Pregnant females were injected with TM [3 mg/40 g body weight] at either E7.5 or E13.5. Only two litters (9 pups total) survived birthing from 7 dams injected at E7.5 and visibly pregnant at late gestation. Of these 9 pups, 1 was a Smn C-T-Neo/C-T-Neo ;Cre Esr1 pup and of similar size and appearance to its littermates. However, in both litters the dams failed to lactate and fostering was unsuccessful.
Birthing and lactation problems are a known common side effect of TM administration, especially when given early during pregnancy [37]. To avert this problem we harvested embryos at E18.5, a late point in gestation, and well after a stage in development (E15.5) in which no viable homozygous Smn C-T-Neo/C-T-Neo embryos had previously been identified (Table 1). DNA prepared from yolk sacs or tails was used for PCR-based genotyping with the same 3-plex PCR assay used in Figures 4 and 5A. This allowed us to identify and determine the efficiency of the floxed pgk-neo cassette excision. The presence or absence of the Cre Esr1 transgene was determined in a separate reaction. In all embryos that carried both the Smn C-T-Neo allele and Cre Esr1 transgene, the injection of TM induced excision of floxed pgk-neo, thus somatically changing the Smn C-T-Neo allele to a Smn C-T allele ( Figure 5B, lanes 5-9). Smn induction of 4 litters at E7.5 resulted in a total of 32 embryos at E18.5 and five were found to be Smn C-T-Neo/C-T-Neo ;Cre Esr1 embryos ( Table 3). All five of these embryos were viable, of similar size and indistinguishable from control embryos ( Figure 5C). In contrast, TM injection of 6 litters at E13.5 resulted in no viable Smn C-T-Neo/C-T-Neo ;Cre Esr1 embryos at E18.5 (0/42) (Table 3). However, in each of these crosses we did identify a Smn C-T-Neo/C-T-Neo embryo that was negative for the Cre Esr1 transgene although both were severely deformed, nonviable and undergoing resorption ( Figure 5C). Chi-square statistics were used to compare the genetic ratios of induced embryos to expected normal mendelian ratios with the assumption that Smn C-T-Neo/C-T-Neo embryos would not be present at E18.5. Genotype ratios from embryos treated at E13.5 were not statistically significant from expected ratios, p = 0.84. However, the genotype ratios of embryos treated at E7.5 were significant, p = 0.05 (Table 3). Thus, increasing Smn levels rescues the embryonic lethality phenotype of Smn C-T-Neo/C-T-Neo ;Cre Esr1 embryos when induced early, but not late in development.
To quantify the level of Smn in these Smn C-T-Neo/C-T-Neo ;Cre Esr1 embryos, we performed western blot analysis and compared them to a series of control, age-matched embryos that titred Smn levels between 100% and 50%. In addition, we were able to extract a small amount of protein from one of the non-viable Smn C-T-Neo/C-T-Neo embryos for comparison to our induced embryos ( Figure 5D). However, without Cre mediated excision of the floxed pgk-neo cassette, Smn levels in this embryo were below the limit of detection even though the loading control, b-tubulin was visualized ( Figure 5D). Densitometry was performed on a separate western blot using the same samples for the other genotypes ( Figure 5C). The excision of the floxed pgk-neo cassette in Smn C-T-Neo/C-T-Neo ;Cre Esr1 +TM embryos increased Smn protein levels to 70% of wild type expression ( Figure 5D). This is greater than the 50% of Smn protein detected in heterozygous Smn null (Smn WT/-) embryos which develop normally and have a normal postnatal lifespan ( Figure 5D) [1]. Furthermore, this is greater than the level of Smn expressed in our Smn C-T-Neo and Smn 2B-Neo progenitor lines of mice that have a normal lifespan and are without phenotype.

Discussion
We specifically designed the targeting vectors used in this study to have a triple function so that a series of Smn alleles could be generated. The first was the introduction of mutations within known Smn exon 7 ESEs to mimic SMN2 exon 7 splicing and attenuate Smn expression. The second was the placement of the positive selection cassette within intron 7 with the aim of further diminishing the amount of Smn generated from these targeted alleles. It has previously been shown that selection cassettes located within introns or regulatory regions, such as pgk-neo that we used here, can hinder expression of targeted genes via transcriptional and/or translation interference either by design ( [38]; additional examples cited in [39]) or inadvertently [40,41,42], which sometimes proves to be serendipitous [42]. The level of interference can be varied depending upon the orientation of the selection cassette if it has cryptic splice donor and acceptor sites, like the neo gene, [39] or they can be engineered. Here we used pgk-neo in the inverted orientation to Smn transcription as the cryptic splice sites were stronger. The third and final function of our design was to flank pgk-neo with loxP sites so that it could be removed with Cre recombinase. This allows the specific analysis of our introduced mutations within the context of a minimally altered genomic locus. Since the neo cassette hindered Smn expression as we designed, our alleles can be used to induce Smn expression while still mimicking SMN2 exon 7 alternative splicing. The conceptual properties of this targeting design are applicable to almost any gene targeting strategy and warrant consideration for those embarking on new projects.
Our allelic targeting strategy provides the opportunity to generate three mouse lines from each single allele. The first is the original progenitor alleles, Smn C-T-Neo and Smn 2B-Neo . The second is these alleles in combination with a tissue specific or inducible Cre transgene for future time and cell-specific induction experiments. Finally, mouse lines possessing the point mutations themselves, Smn C-T and Smn 2B , can be produced. Here we have focused on characterizing the first two lines of mice.
Mice heterozygous for the Smn C-T-Neo and Smn 2B-Neo alleles were normal. When homozygous, these alleles caused embryonic lethality, even though full-length transcripts and small amounts of Smn protein could be detected. This result illustrates once again that a minimum amount of Smn is required by all cell types [1,34,35,43,44], and this appears to be about 5% during development in mice. Although we found no significant difference in mendelian ratios of homozygous mutants for either allele at E9.5, morphologically it was clear that the embryos were dead or extremely growth retarded and their ability to develop corresponded to their Smn levels. Embryonic lethality during this period of development is commonly caused by potential failures in gastrulation, defects in extra embryonic membrane functions such as vasculogenesis or hematopoiesis and/or cardiovascular failure [45]. Considering these possibilities, we were able to visualize swollen pericardial sacs in several of our Smn C-T-Neo/C-TNeo homozygous mutants at E11.5 (data not shown) or E12.5 that were not grossly deformed. Table 3. Genotypes of Smn embryos at E18.5 exposed to tamoxifen at E7.5 or E13.5. Functionally and molecularly the homozygous Smn C-T-Neo/C-T-Neo and Smn 2B-Neo/2B-Neo hypomorphs are less severe than Smn D7/D7 homozygotes as they express small amounts of fully functional Smn protein and live slightly longer (E12 and E9 vs E7) [34,35]. The Smn C-T-Neo/C-T-Neo homozygotes are generally less severe than the Smn 2B-Neo/2B-Neo homozygotes due to the nature of the introduced mutations within exon 7 since the C-T mutation produces more FL-Smn transcripts than the 2B mutation. During the course of our molecular analyses there were two unexpected observations. First, we found that D7Smn transcripts from Smn 2B-Neo/2B-Neo embryos were extremely high (12.4463.44) vs. heterozygous Smn 2B-Neo embryos (1.7260.23). This may seem odd at first glance, but SMN together with other proteins functions in the assembly of small nuclear ribonucleoproteins (snRNPs), which are critical for pre-mRNA splicing [46,47]. It has previously been demonstrated that low levels of SMN cause changes in snRNP abundance and splicing alterations [48,49,50], so it is possible that SMN regulates its own splicing of SMN2 exon 7. In fact, Jodelka et al. (2010) [51] has recently identified a feedback loop in which low SMN levels exacerbate SMN2 exon 7 skipping. This result helps explain the high degree of D7Smn transcripts from our Smn 2B-Neo/2B-Neo embryos since they produce only 1-3% Smn protein. The second observation was the low amount of Smn protein (,5%) as compared to FL-Smn transcripts (10-20%) in our homozygous embryos. We predict this is caused by a combination of the degenerative state of the embryos, lack of higher order Smn complexes that can stabilize the protein, and the presence of the floxed pgk-neo cassette (as we designed), which creates hybrid Smn/neo transcripts and exerts transcriptional and translational repression. We show that removal of the pgk-neo cassette is able to relieve this repression.
As progress in developing SMN-dependent therapies moves forward, our understanding of when and where SMN is required for severe, intermediate and mild forms of SMA becomes important. This can be addressed using animal models since they can be genetically manipulated. SMA has already been modeled in a number of different organisms and each has its strengths [52,53], but the most widely used to date have been SMA mouse models. The mouse models fall into two categories:1) transgenics bred onto Smn null or D7 backgrounds to rescue the embryonic lethality of homozygous Smn mutants to produce varying degrees of SMA severity, and 2) modifications of the endogenous Smn locus that reduce Smn expression. One conditional allele of Smn has been generated, a floxed allele of Smn exon 7, which can be combined with varying Cre transgenes for the temporal or spatial depletion of Smn. Although this is a very useful allele and conditional depletion experiments have been done [34,43,44], SMA is due to a paucity of Smn protein not complete absence of Smn protein. Currently lacking, and which we begin to fulfill here, is a panel of different Smn inducible alleles that can be used in future experiments to address the cellular and temporal requirements of Smn induction in varying SMA disease severities.
To validate the potential of Smn C-T-Neo and Smn 2B-Neo to be utilized as inducible alleles, we used Smn C-T-Neo as a proof of concept allele. Using Smn C-T-Neo in combination with a tamoxifen inducible Cre transgenic mouse, Cre Esr1 , we derived primary MEF lines and proved that only in the presence of tamoxifen was Smn induced. This illustrates the efficacy of Smn induction in vitro and the potential of using these lines to establish Smn inducible culture models. In addition, a single i.p. injection of tamoxifen was able to excise the floxed pgk-neo cassette in somatic tissues of adult mice and embryos. Hence, the alleles can be used in future somatic experiments to assist in determining the cellular requirements of Smn. This can be achieved through genetic crosses of tissuespecific Cre lines or as shown here, through injections if the Cre lines are tamoxifen inducible. In addition, if the Smn C-T-Neo and/or Smn 2B-Neo is used as the Smn mutant background in combination with SMN2 transgenic mice to achieve postnatal survival, new SMA models can potentially be generated with varying degrees of severity. Thus, the timing requirements of Smn inductive therapies could be addressed postnatally in severe, intermediate and mild forms of SMA. We are currently working to develop these models and determine this.
In a final experiment, we addressed whether the embryonic lethality of Smn C-T-Neo/C-T-Neo embryos could be rescued. We found that we could, if induction occurred early, around gastrulation (E7.5), but not late (E13.5), and the mutant embryos that were induced at E7.5 expressed ,70% Smn protein. This level of Smn protein is well above that of Smn +/2 mice that have a normal lifespan [1] or heterozygous SMA model mice [(SMN2)Ahmb89 +/+ ;Smn +/2 ; Jax strain 5024], which have no motor neuron loss and a normal lifespan [54]. At this point our work is unable to address the dosage and timing of Smn expression necessary to alleviate postnatal SMA disease, which is the time period when all, but the very most severely affected, SMA patients present with symptoms. However our results are important as they are consistent with the few pharmacological or gene therapy studies where a therapeutic window of opportunity to demonstrate a survival or functional benefit exists in severe SMA [15,17,29]. We all show that the earlier the intervention, the better the outcome. The mounting results of these types of studies are important points of consideration as clinical trials based on SMNinductive therapies are designed, especially for the most severe SMA patients. It will be important for future studies to add and extend this work. For example, a paramount point is whether SMN inductive therapies can provide benefit during the lag/plateau phase of disease or prevent further deterioration of function from the point of treatment. We believe that the alleles we have generated here will be useful in developing the appropriate models to answer this question.
In conclusion, the gene targeting strategy that we utilized is applicable to almost all gene targeting projects. The strategy provides the potential to generate multiple lines of mice, including an inducible allele, from a single targeting event for the cost of extra effort put into the planning stage of vector design. As proof, we generated an allelic series of Smn mice. They produce small amounts of Smn, mimic SMN2 splicing and are inducible. While these are the first inducible Smn alleles to be described in the literature, other groups are also working to generate inducible Smn mice using different strategies such as Tet-on/off systems or other Cre-inducible alleles. As proven with the various transgenic models of SMA, all will play important and complimentary roles as we move forward to understand Smn function in health and disease, and progress towards developing a therapy for SMA.

Construction of targeting vectors and generation of Chimeras
The replacement vectors, p(Smn C-T-Neo ) and p(Smn 2B-Neo ) are shown schematically in Figure 1A. The total length of homology between the targeting vector and the endogenous Smn locus is 6.5 kb; the long arm is 5.0 kb and the short arm is 1.5 kb. The positive selection cassette, flox-pgk-neo was inserted into the unique BamHI site 180 bp distal to exon 7. This was done to increase the chance of homologous recombinant clones containing the C-T transition in exon 7 or the 2B mutation (GGA-TTT) in exon 7, since recombination is unlikely to occur within such a short distance between our modification and the positive selection cassette. The mutations were introduced via site directed mutagenesis of a smaller fragment and then re-subcloned into the targeting construct to avoid potential mutations generated by PCR. In total, after Cre excision of the pgk-neo cassette, ,90 bp will remain, of which, 34 bases correspond to the remaining loxP site. The 90 bp of sequence is located sufficiently distal to exon 7 and should not affect regulation or processing of the Smn C-T-Neo and Smn 2B-Neo transcripts. The targeting constructs were electroporated into 129 ES cells and 4 independent homologous recombinant clones for each construct were identified. Two from each construct were used to generate chimeras by microinjecting ES cells into C57Bl/6 blastocysts.

Mice and Animal Care
Animals were kept in a controlled vivarium at 25uC and 50% humidity in a 12 hour light/12 hour dark photoperiod and monitored for health. Colonies were maintained by breeding mice heterozygous for the Smn mutant alleles. The official name for Smn C-T-Neo/+ mice is Smn tm2Cdid . It is being placed at The Jackson laboratory in both C57BL/6 and FVB/N genetic backgrounds but currently lacks official strain designation. The official name of the Smn 2B-Neo/+ mice is Smn tm1Cdid and it is also being placed at The Jackson Laboratory in both C57BL/6 (Jax strain 008838) and FVB/N (JAX 008837) genetic backgrounds. The lines will be made available once they are on congenic C57Bl/6 and FVB/N genetic backgrounds.

RNA Transcript Analysis
RNA was extracted from tissues using TRIzol reagent (Invitrogen) in accordance with the manufacturer's directions. Samples were then treated with TURBO DNA-free reagents (Ambion) and first strand cDNA was prepared using SuperScript TM II Reverse Transcriptase (Invitrogen) and random hexamer primers (Roche, Nutley, NJ) according to the manufacturer.
qRT-PCR was performed on cDNA prepared as described above. All reactions were performed in triplicate in a 20 ul final reaction volume. Since the assay on demand primer and probe available from ABI for Smn exon 7 are too close or overlap the C-T and 2B mutations and could hinder interpretation of results, we designed and validated FL-Smn and D7Smn assays to specifically amplify Smn transcripts with similar efficiencies between the WT, C-T and 2B mutations and not cross react with human SMN. Once validated these assays were prepared by ABI in a 20X mastermix to be similar to an assay on demand. FL-Smn was amplified and detected with primer #ABI-1, Smn678F (59-TGGCTACCACACTGGCTAC-TATATG), primer #ABI-2, Smn678R (59-GACACCCCATC-TCCTGAGACA) and probe ABI-3, Smn678M1 (6FAM-CATA-CAAATTAAGAAGTTCAGC). D7Smn transcripts were amplified and detected with primer #ABI-4, Smn_EX6_8F (59-GGCAG-TATGCTAATCTCTTGGTACA), primer #ABI-5, Smn_EX6_ 8R (59-CGACACCCCATCTCCTGAGA) and probe #ABI-6, Smn_EX6_8M1 (59-6FAM-CAGAGCTGAACCATATAGTAG-C). mGapdh On Demand Assay (Applied Biosystems) was used as an internal control for normalizing data. All qRT-PCR reactions were run using an Applied Biosytems 7500 Fast Real-Time PCR System utilizing the following conditions: 1 cycle: 2 min 50uC, 1 cycle: 10 min 95uC, 40 cycles: 15 sec 95uC, 1 min 60uC. All data was analyzed using the DDCt method.

Protein isolation, western blot and densitometry
Tissues and embryos were homogenized as previously described [55]. Primary antibodies used were mouse monoclonal antibodies to Smn (BD Translabs) at 1:5,000 and b-tubulin at 1:20,000. Polyclonal rabbit actin at 1:1,000. The secondary antibody, goat anti-mouse (BioRad) or goat anti-rabbi (BioRad) were used at 1:10,000. Membranes were exposed to chemiluminescence (ECL Western Blotting Detection Reagents, Amersham Biosciences) and developed on Kodak film. Blots were imported into Adobe Photoshop using Microtek 1000XL scanner and quantified through densitometry by Openlab 5.0 software. The Li-Cor Odyssey System was used to quantify embryo extracts in Figure 3 according to the instructions of the manufacturer (Li-Cor Biosciences). Briefly, proteins were resolved on a 4-12% Bis Tris NuPage pre-cast gel system using MES running buffer and transferred to nitrocellulose using the I-Blot transfer system (Invitrogen). Bound antibodies were detected using IR-Dye800CW-conjugated goat anti-mouse IgG (Li-Cor). The intensity of each band was measured and normalized to that obtained from Tubulin.

Whole Mount Embryo Images
Pregnant female mice were sacrificed by CO 2 asphyxiation followed with cervical dislocation. Embryos at either E9.5, E12.5 or E18.5 were captured on a Leica upright dissecting microscope and digital camera at 2.0X, 1.0X, and 0.8X magnifications respectively. Embryos at E11.5 were captured at 1.0X. Photographs were taken at a 300dpi, 8 bit/channel quality.

pgk-neo excision by TM in MEFs
Pregnant females were sacrificed with CO 2 asphyxiation at 14.5 days post coitum (dpc). Embryos were individually eviscerated and rinsed in 1X PBS for MEF preparation. Yolk sac was collected for DNA to identify Smn C-T-Neo/+ ;Cre Esr1 embryos. Embryos were finely minced with a straight edge razor and incubated in trypsin at 37uC. Debris were removed by resuspending cells in 15cc tube containing cell growing media (Earle's alpha-MEM, 10% FBS, 1% pen/strep, 1% non-essential amino acids, 1% L-glutamine) and allowing large debris to collect at the bottom. The supernatant was plated and cells were passaged 4 times before those with the genotype Smn C-T-Neo/+ ;Cre Esr1 were used for experiments. TM (1 mM) was added to cultures for 1 hr to induce CRE activity. Control cells received no TM. After 24 hours cells were harvested for DNA and RNA as previously described for tissue samples.

pgk-neo excision by TM in adult and embryonic mice
Injection of TM to both adult and embryo used here, were carried out as previously described [37]. TM was diluted to 10 mg/ml in corn oil. Adults were injected with 9 mg TM/40 g body weight and sacrificed five days later. Tissues harvested included spinal cord, skeletal muscle (gastrocnemius and quadriceps), cortex, cerebellum, heart and kidney. Both DNA and RNA were extracted as previously described. For embryonic induction, pregnant females were injected at 7.5 dpc or 13.5 dpc with 3 mg TM/40 g of body weight. At 18.5 dpc, females were sacrificed with CO 2 asphyxiation and embryos dissected individually. From each embryo the lung was harvested for DNA and the remainder flash frozen in liquid nitrogen and stored at 280uC.